Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years. And while that falls short of qualifying the stock as a Dividend Aristocrat, its current yield of 6.29%—or $1.72 per share annually—has helped PFE find its way into many portfolios.
However, from a share appreciation standpoint, Pfizer has lost some of its appeal. After reaching its all-time high (ATH) on Dec. 17, 2021, driven by increased demand for its COVID-19 vaccine, Comirnaty, the stock has declined by nearly 47%.
